share_log

Citigroup Downgrades Cano Health to Neutral, Lowers Price Target to $0.8

Benzinga ·  Aug 11, 2023 17:36

Citigroup analyst Jason Cassorla downgrades Cano Health (NYSE:CANO) from Buy to Neutral and lowers the price target from $4 to $0.8.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment